Novel therapies for the treatment of prostate cancer: Current clinical trials and development strategies Journal Article

  

Authors:	Morris, M. J.; Scher, H. I.
Article Title:	Novel therapies for the treatment of prostate cancer: Current clinical trials and development strategies
Abstract:	The number of treatment options for patients with prostate cancer is expanding, as mechanism-based therapies enter clinical testing. Such strategies are based on manipulating tumoral genetics, cell signaling, apoptosis, angiogenesis, the immune system, and others. To properly develop these agents, traditional trial designs and outcome measures require reconsideration. This review describes these novel drugs and their targets using a clinical states model. Investigators use a clinical states model as a framework for matching specific agents with the needs of the treatment population and the biology of the tumor at any given point in the natural history of the disease. © 2002 Elsevier Science Ltd. All rights reserved.
Keywords:	signal transduction; platelet derived growth factor; vasculotropin; protein expression; thalidomide; clinical trial; nonhuman; adjuvant therapy; prostate specific antigen; protein bcl 2; unindexed drug; cancer immunotherapy; apoptosis; dendritic cell; thrombocytopenia; epidermal growth factor receptor; hypercalcemia; calcitriol; drug effect; angiogenesis; cetuximab; protein p53; genetic vectors; docetaxel; fever; prostate cancer; prostate-specific antigen; prostatic neoplasms; malaise; prostate specific membrane antigen; immunotherapy; prostatectomy; gene therapy; vorinostat; biologic therapy; thymidine kinase; adenovirus vector; mucin 1; trastuzumab; angiogenesis inhibitors; vitamin d receptor; peroxisome proliferator activated receptor gamma; rosiglitazone; drug tolerance; ganciclovir; clinical trials; fibroblast growth factor; genes, p53; adenoviridae; keyhole limpet hemocyanin; fumagillol chloroacetylcarbamate; geldanamycin; hypercalciuria; atrasentan; qs 21; nephrolithiasis; endothelin 1; estramustine; retinoid x receptor; antineoplastic therapy; troglitazone; humans; human; male; priority journal; article; herbimycin; vitamin d responsive element
Journal Title:	Surgical Oncology
Volume:	11
Issue:	1-2
ISSN:	0960-7404
Publisher:	Elsevier Inc.
Date Published:	2002-06-01
Start Page:	13
End Page:	23
Language:	English
DOI:	10.1016/s0960-7404(02)00006-3
PUBMED:	12031864
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-0036273771&partnerID=40&md5=6b6c519e22f57f6a8b965e24dddfb4ab
Notes:	Export Date: 14 November 2014 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/66787